NASDAQ$BMEA
Biomea Fusion Inc · Q2 2022 earnings
Q2 2022 earnings · · Investor relations
Briefing
Second quarter 2022 financial results and business highlights reported.
Biomea Fusion reported its second quarter 2022 financial results, highlighting progress in advancing BMF-219 in oncology and type 2 diabetes, selection of BMF-500 as a second IND candidate, and a cash position of $150.2 million.
- Continued to make significant progress advancing BMF-219 in multiple oncology indications.
- Expanded clinical development strategy for BMF-219 to include type 2 diabetes.
- Announced selection of second IND candidate, BMF-500, a potential best-in-class, oral, covalent inhibitor of FLT3.
- Cash position of $150.2 million at the end of the second quarter of 2022.
Headline financials
Revenue & EPS history
Biomea Fusion · Revenue · Quarterly
$1.07B
Forward guidance
The company is on track to submit IND for BMF-219 in solid tumors and type 2 diabetes in the second half of 2022 and continues IND-enabling studies for BMF-500.
Tailwinds
- On track to submit IND for BMF-219 in solid tumors in the fourth quarter of 2022.
- On track to submit IND for BMF-219 in type 2 diabetes in the second half of 2022.
- Upcoming two oral presentations at the 2022 annual meeting of the European Association for the Study of Diabetes (EASD) in September.
- Advancing toward the clinic with second IND candidate, BMF-500, a covalent FLT3 inhibitor with best-in-class potential.
- BMF-219 exhibited robust anti-tumor effect in cell lines and PDX models in DLBCL and MM cell lines
Historical earnings impact
How earnings announcements have historically affected this stock's price.
Avg. return before/after earnings
Based on 17 quarterly earnings reports · overlaid with Q2 2022
+5.2%
Avg return
Earnings day
+3.3%
Avg return
5 days after
+3.0%
Avg return
30 days after
40%
8 / 20 earnings
Positive
+109.7%
Q4 2022
Best reaction
-16.7%
Q3 2024
Worst reaction
| Quarter | Report date | Reaction (Day 0) | +5 days | +30 days |
|---|---|---|---|---|
| Q4 2026 | +15.3% | -13.5% | -23.7% | |
| Q3 2025 | -0.7% | -4.3% | -21.0% | |
| Q2 2025 | +0.6% | -3.2% | +21.5% | |
| Q1 2025 | -1.3% | -4.6% | +73.0% | |
| Q4 2024 | +1.2% | -7.8% | -8.7% | |
| Q3 2024 | -16.7% | -27.2% | -43.4% | |
| Q1 2024 | +6.7% | +3.7% | -9.1% | |
| Q4 2023 | -14.4% | -14.8% | -22.6% | |
| Q3 2023 | -6.8% | -7.9% | +16.3% | |
| Q2 2023 | -2.4% | -9.3% | -22.2% | |
| Q1 2023 | -3.3% | +2.6% | +12.5% | |
| Q4 2022 | +109.7% | +101.0% | +84.6% | |
| Q3 2022 | -15.6% | -29.4% | -43.3% | |
| Q2 2022 | +3.3% | +11.8% | +8.5% | |
| Q1 2022 | +35.2% | +69.4% | +127.2% | |
| Q4 2021 | -13.8% | -7.7% | -36.2% | |
| Q3 2021 | +7.6% | +2.0% | -7.9% | |
| Q2 2021 | -0.6% | -11.0% | -3.4% | |
| Q1 2021 | -0.3% | +7.9% | -21.4% | |
| Q4 2020 | -0.3% | +7.9% | -21.4% | |
| Q3 2020 | — | — | — | |
| Q2 2020 | — | — | — | |
| Q1 2020 | — | — | — |
Discussion
Share your read of this quarter. Sign-in carries your eToro identity.
Join the conversation
Sign in with eToro to post your read of this quarter and vote on others'.
Sign in with eToro